FY2029 EPS Estimates for GH Research Lifted by HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright boosted their FY2029 earnings estimates for shares of GH Research in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.13 for the year, up from their previous forecast of $0.10. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

Several other research firms have also recently weighed in on GHRS. Canaccord Genuity Group cut their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Cantor Fitzgerald began coverage on shares of GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target on the stock. Finally, Stifel Nicolaus increased their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, GH Research presently has a consensus rating of “Buy” and an average target price of $30.60.

GH Research Trading Up 1.3 %

GHRS stock opened at $10.55 on Thursday. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50. The firm has a market cap of $548.90 million, a PE ratio of -13.35 and a beta of 0.94. The business’s 50-day moving average price is $10.73 and its two-hundred day moving average price is $9.20.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06.

Institutional Investors Weigh In On GH Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. RA Capital Management L.P. raised its stake in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after purchasing an additional 85,000 shares in the last quarter. Lynx1 Capital Management LP increased its holdings in GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after buying an additional 663,100 shares during the last quarter. Diadema Partners LP bought a new stake in GH Research during the fourth quarter worth $711,000. Woodline Partners LP lifted its stake in GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock valued at $553,000 after acquiring an additional 41,711 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after acquiring an additional 3,092 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).